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Human umbilical cord blood (UCB) is a potential
ource of hematopoietic stem cells (HSCs) capable of
econstituting hematopoiesis after myeloablative [1-4]
r nonmyeloablative [5] therapy. As a result of the
arly successes with UCB transplantation (UCBT)
rom sibling donors [6], unrelated donor UCB bank-
ng programs have been initiated in many countries
round the world. Furthermore, over the last decade,
ncreasing experience has been gained in performing
ransplantation in children [1-4] and adults [5,7-10]
ith hematologic malignancies and nonmalignant dis-
rders [11], with promising results. However, to date,
o randomized studies of UCB versus unrelated vol-
nteer HSC transplantation have been performed,
nd many unanswered questions concerning UCBT
emain. The decision of whether to use UCB over
nrelated volunteer HSCs is further complicated by
he fact that the deﬁnition of a “suitably matched”
olunteer has not been clearly established. To help
nswer the question of “who should get UCB” as the
SC source of choice, the current status of unrelated
onor UCBT will be reviewed, with a focus on hema-
ologic malignancies.
SSUES OF CELL DOSE AND HLA MATCH
The chief known beneﬁts of unrelated donor UCB
re rapid availability [12], with the absence of donor
ttrition, and, for a given degree of HLA match, a
ecreased incidence of graft-versus-host disease
GVHD) compared with that seen after transplanta-
ion of unrelated volunteer bone marrow (BM) or
eripheral blood [1-4]. These attributes have made
CB an attractive HSC source for patients requiring
rgent transplantation or those without a suitably
atched adult volunteer donor. In particular, emerg-
ng data indicate that the reduced stringency of HLA
atching has increased racial and ethnic minorities’
ccessibility to transplantation. For example, the g
8OBLT study included 37% minority patients who
nderwent successful transplantation, despite the fact
hat only 30% of the recipients received units that
ere 8-10/10 allele-matched [13]. The ethnic and
acial breakdown of a recent series of 17 double-unit
CBT recipients who underwent transplantation at
emorial Sloan-Kettering Cancer Center (MSKCC)
s shown in Table 1. These units were a median of
/10 matched to the recipient (range, 3/10-8/10), with
5 of 16 evaluable patients engrafting and no patient
xperiencing grade 4 acute GVHD to date.
However, a chief limitation of UCB is low cell
ose. Multiple studies have demonstrated the devas-
ating impact of low cell dose on engraftment, trans-
lantation-related mortality (TRM), and survival
2-4,7]. For example, a study of 102 patients (median
ge, 7.4 years) who underwent transplantation with a
ingle unit after myeloablative conditioning found a
-year TRM of 30% (95% conﬁdence interval [CI] 
1%–39%). However, TRM was strongly associated
ith CD34 cell dose, with TRM  70% in patients
eceiving grafts with a CD34 dose  1.7  105
ells/kg4. This translates to a 1-year survival of 70%
95% CI  49%–90%) in patients receiving  1.7 
05 CD34 cells/kg and very poor survival in patients
ith grafts with lower CD34 doses. The limitation
f cell dose contributed to inferior hematopoietic re-
overy and increased TRM in adult single-unit UCBT
ecipients (n  150) compared with 6/6 matched un-
elated volunteer BM recipients (n 367) reported by
aughlin et al. [8]. However, given that the disease-
ree survival after UCBT was comparable to that of
LA-mismatched BM recipients (n  83), this has
ntroduced adult UCBT as a valid alternative to the
se of HLA-mismatched volunteer donors. Although
similar comparison by Eurocord revealed compara-
le outcomes after unrelated donor BM transplanta-
ion and UCBT [9], and other series have shown
onsiderably better outcomes after myeloablative sin-
le-unit UCBT [14-16], there is no doubt that novel
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Who Should Get Cord Blood Transplants? 79trategies are needed to improve the outcome of adult
CBT, particularly in the United States.
In addition to cell dose, increasing data have dem-
nstrated the critical importance of HLA match on
CBT outcome. For example, unpublished data from
he New York Blood Center have shown that for
atients with hematologic malignancies to achieve a
-year survival of  50% after myeloablative single-
nit UCBT, the cryopreserved cell dose must be at
east 2.5  107 nucleated cells (NCs)/kg in recipients
f 5/6 units. In contrast, recipients of 4/6 units must
eceive a cell dose of at least 5  107 NCs/kg to
chieve at least 50% survival. This suggests that im-
roved HLA match can compensate for low cell dose,
r, conversely, that HLA mismatch must be compen-
ated for by a larger cell dose. This argument is sup-
orted by the fact that to date, no association between
C dose and survival after the transplantation of 6/6
nits has been demonstrated (Rubinstein P, and
tevens C, personal communication). Therefore, the
eﬁnition of “satisfactory” UCB dose likely depends
n the match of the unit. A further study of the affect
f NC dose and 3-6/6 HLA match on postengraft-
ent TRM revealed that in engrafting patients, an
ncrease in cell dose above 2.5  107 NC/kg was not
ssociated with any further protection from TRM
igure 1.Day 30-180 TRM in 607 3-6/6 HLA-matched single-unit
yeloablative UCBT recipients who engrafted according to HLA
able 1. Ancestry of 17 Double-Unit Transplant Recipients at
SKCC, October 1, 2005–September 30, 2006
Ancestry n
orthwestern European 0
frican-American 4
sian 1
iddle Eastern 1
entral/ South American 5
outhern European 2
astern European 2
ixed 2
atients were offered UCBT if allogeneic transplantation was in-
dicated and no suitably matched unrelated volunteer donor was
available.Tismatch (New York Blood Center data [17]).17]. In contrast, increasing mismatch was associated
ith an increasingly adverse impact on TRM at every
evel of mismatch (Figure 1). These ﬁndings empha-
ize the importance of considering both match and
ell dose in unit selection. Further, if strategies could
e devised to nearly guarantee engraftment, then pa-
ient outcomes might be improved by optimizing
atch over dose.
The importance of HLA match has recently been
ighlighted in the comparison of the outcomes of
-6/6 HLA-A and -B antigen and -DRB1 allele-
atched UCBT with those of 8/8 allele-matched un-
elated volunteer donor transplants in children age 
6 years with leukemia [18]. This analysis revealed
uperior leukemia-free survival (LFS) after 6/6-
atched UCBT (n  35) and comparable LFS in 8/8
llele-matched BM (n  116) and 5/6-matched (n 
01) or 4/6-matched (n  267) UCB recipients
Table 2). Notably, compared with 8/8 allele-matched
MT, TRM was comparable in matched and high cell
oses ( 3  107 NC/kg) 5/6 matched UCBT. Fur-
hermore, although TRM was higher in recipients of
ow cell dose ( 3  107 NC/kg) 5/6 and 4/6 (any cell
ose) UCBT, relapse was lower in these patients,
ccounting for the similarity in LFS compared with
M recipients. These results support the preference
f HLA-matched or -mismatched UCB of adequate
ell dose over BM in treating children with leukemia.
urthermore, if engraftment can be improved, as has
een seen with more recent experience using ﬂudara-
ine-based conditioning, for example, then the argu-
ent in favor of pediatric UCBT will be strengthened
ven further, due to the lower incidence of chronic
VHD and the likely consequent improvement in
uality of life.
OVEL STRATEGIES TO IMPROVE UCBT OUTCOME
N ADULTS
Currently, most adult patients will not have any
/6 HLA-A or -B antigen and -DRB1 allele-matched
nits, or any single 5/6 or 4/6 units of satisfactory dose
eg, 5/6 2.5 107 NCs/kg, 4/6 5 107 NCs/kg).
able 2. Comparison of Unrelated Donor HSCT in Children with
cute Leukemia18
HSC Source TRM Relapse LFS OS
/8 allele-matched BM 19% 41% 38% 45%
LA-A, -B antigen, -DRB1
allele-matched UCB
6/6 6% 34% 60% 63%
5/6 > 3.0 x 107 NCs/kg 29% 31% 41% 45%
5/6 < 3.0 x 107 NCs/kg 43% 21% 37% 36%
4/6 49% 20% 33% 33%
FS indicates leukemia-free survival; OS, overall survival.herefore, along with enlarging the global UCB in-
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J. N. Barker80entory, novel strategies are required in adult UCBT.
x vivo expansion [19,20] and the use of haploidenti-
al HSCs [21] to ameliorate the prolonged neutrope-
ia associated with adult UCBT are currently under
nvestigation. An alternative approach is to use dou-
le-unit grafts to augment graft cell dose [10]. This
pproach in 31 double-unit recipients (median age, 24
ears; range, 13-53 years) with hematologic malignan-
ies was associated with sustained neutrophil engraft-
ent in all evaluable patients (n  29) at a median of
3 days (range, 14-41 days) despite the fact that this
ngraftment was accounted for by 1 unit of relatively
ow cell dose (median infused cell dose of 1.8  107
Cs/kg [range, 0.7-3.6 NCs/kg] and 1.7  105
D34 cells/kg [range, 0.4-10.4 cells/kg]). With a
edian follow-up of 1.2 years (range, 55 days–3.2
ears), the disease-free survival at 2 years was 60%
95% CI  41%–79%) in all patients and 68% (95%
I  47%–89%) in patients who underwent trans-
lantation while in remission (n 23) (Figure 2). This
ndicates that double-unit UCBT can be performed
afely in adults with improved engraftment and re-
uced TRM compared with single-unit historical con-
rols. Of further interest is that preliminary data have
uggested that double-unit UCBT may be associated
ith a reduced incidence of relapse [22].
Although double-unit UCBT is an intriguing
trategy for augmenting graft cell dose, factors inde-
endent of cell dose likely also contribute to the poor
esults associated with the early investigation of
CBT in adults. For example, older patients with
xtensive previous therapy or signiﬁcant comorbidities
ill be at high risk for TRM independent of graft cell
ose with conventional myeloablative conditioning
egimens. For these patients, reduced-intensity (RI) or
onmyeloablative (NMA) conditioning is a potential
lternative [5]. Notably, however, after a regimen of
yclophosphamide 50 mg/kg, ﬂudarabine 200 mg/m2,
nd total body irradiation 200 cGy in 59 adults (me-
ian age, 49 years [range, 19-60 years]) with advanced
ematologic malignancies, the incidence of sustained
igure 2. Disease-free survival after double-unit myeloablative
CBT (n  31) [10].onor engraftment was associated with previous ther-
py (Figure 3). This suggests that the lack of previous
herapy can promote graft rejection. The optimal pre-
arative regimen for guaranteeing donor engraftment
n patients with such disorders as myelodysplasia
MDS), myeloﬁbrosis, or chronic myelogenous leuke-
ia who are both unsuitable for ablative conditioning
nd without previous chemotherapy remains to be
stablished. The consequences of adding antithymo-
yte globulin to this NMA regimen as a strategy to
acilitate engraftment has been demonstrated by
runstein et al. [23] with a 21% incidence of Epstein-
arr virus–related complications. Furthermore, al-
hough TRM with this NMA regimen was relatively
ow (14%) in patients age  45 years and not prohib-
tive (24%) in those with extensive previous therapy, it
as high (44%) in those with poor performance status
r serious comorbidities, indicating that such patients
ay be better served with nontransplantation therapy.
his dataset was recently updated with a 2-year pro-
ression-free survival of 43% (95% CI  31%–55%)
n 95 patients [24]. Investigation should now concen-
rate on disease-speciﬁc outcomes after NMA UCBT
25], as well as strategies to ensure engraftment in
atients without intensive previous therapy.
NRESOLVED QUESTIONS IN UCBT
Although UCBT outcomes are promising, numer-
us unresolved issues remain. The most prominent
uestions in UCB graft selection include the follow-
ng:
How many banks should be searched?
What is the minimum acceptable NC dose for
each level of match using 4-6/6-matched units?
Should CD34 dose be considered in unit
selection?
What is 1 step down in antigen match worth in
cell dose?
What is the importance of the vector of
igure 3. Sustained donor engraftment after NMA UCBT using
yclophosphamide 50 mg/kg, ﬂudarabine 200 mg/m2, and total
ody irradiation 200 cGy, according to previous therapy (n  59).mismatch?
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Who Should Get Cord Blood Transplants? 81Does the losing unit in a double-unit graft facil-
itate the engraftment of the winner?
Does the use of double units inﬂuence the risk of
leukemic relapse?
What is the deﬁnition of a satisfactory single unit,
or who should receive a double-unit graft?
What are the minimum criteria for the NC dose
of each unit in a double-unit graft?
Should graft selection criteria be different for
malignant and nonmalignant diseases?
Additional important questions include the fol-
owing:
What are the optimal conditioning regimens in
the ablative and nonablative settings?
What is the optimal GVHD prophylaxis?
What is the optimal methodology for thawing of
red cell–depleted units and red cell–containing
units?
What is the potency of the graft-versus-malig-
nancy effect in speciﬁc diseases?
UMMARY
Who should receive a UCBT? Currently, UCBT
s a valid alternative for any patient requiring unrelated
onor transplantation without a suitably matched and
eadily available unrelated volunteer. The MSKCC
trategy for hematologic malignancies is outlined in
igure 4. In patients age  16 years with leukemia,
merging data indicate that outcome is superior with
atched UCB and comparable with 4-5/6 matched
nits, suggesting that UCB should take priority over
M, particularly if there is a 6/6 unit, or a 5/6 unit
ith a dose  3  107 NCs/kg. In adults, the priority
f unrelated volunteer HSCs versus UCB will depend
n the strategy for preventing GVHD using unrelated
olunteer HSCs (particularly in the setting of mis-
atch) and on the strategy for augmenting the UCB
igure 4. MSKCC unrelated donor and protocol algorithm for
igh-risk hematologic malignancies in patients age 4-70 years with-
ut an HLA-matched sibling donor. A strong preference for unre-
ated volunteer donors is given for patients with myeloﬁbrosis and
anconi’s anemia.raft cell dose. Furthermore, if the patient is only a
andidate for an RI or a NMA regimen, then the
atient’s diagnosis and previous therapy must be con-
idered when selecting the optimal pretransplantation
herapy to ensure donor engraftment. Finally, because
electing a UCB graft is more complicated than se-
ecting an unrelated volunteer donor, transplantation
t centers with UCBT expertise is ideal. Centers
hould be encouraged to have a written algorithm
ictating the minimum criteria of cell dose and HLA
atch, as well as an approach to trading off dose and
atch, to guide search coordinators in unit selection.
A randomized trial of unrelated volunteer HSC
nd UCB is needed. However, the logistics of such a
tudy are challenging, and whether or not such a study
ill be feasible is unclear. In the meantime, transplant
enters are strongly encouraged to enroll patients on
ither “in-house” innovative protocols or multicenter
tudies. Two important US multicenter studies enroll-
ng patients with high-risk leukemia and MDS are the
lood and Marrow Transplant Clinical Trials Net-
ork study, randomizing pediatric patients to single
ersus double UCB units, and the Center for Inter-
ational Transplant Research–sponsored multicenter
tudy of double-unit UCBT in adults.
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